Rawdah Karwt, Oksana V Bondar, Mikhail V Pugachev, Tharaa Mohammad, Aisylu S Kadyrova, Roman S Pavelyev, Saleh Alrhmoun, Oleg I Gnezdilov, Yurii G Shtyrlin
Doxorubicin (DOX) is a prevalent anticancer agent; however, it is unfortunately characterized by high cardiotoxicity, myelosuppression, and multiple other side effects. To overcome DOX limitations, two novel pyridoxine-derived doxorubicin derivatives were synthesized (DOX-1 and DOX-2). In the present study, their antitumor activity and mechanism of action were investigated. Of these two compounds, DOX-2, in which the pyridoxine fragment is attached to the doxorubicin molecule via a C3 linker, revealed higher selectivity against specific cancer cell types compared to doxorubicin and a promising safety profile for conditionally normal cells...
February 20, 2024: Life